CWA
LCTX icon

Clarus Wealth Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

Clarus Wealth Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-10,147
Closed -$10K – 155
2019
Q3 		$10K Buy
+10,147
New +$10.5K 0.01% 144

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return

Clarus Wealth Advisors's LCTX Position: Q4 2019 in Review

Clarus Wealth Advisors sold out of Lineage Cell Therapeutics (LCTX) in Q4 2019, closing a stake of 10,147 shares — an estimated $10K sold.

Clarus Wealth Advisors first reported a position in LCTX in Q3 2019 and held it in 1 quarter. The position peaked at $10K in Q3 2019. 108 funds tracked by Wall St. Rank hold LCTX as of Q4 2019.

  • Clarus Wealth Advisors reported no remaining Lineage Cell Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Clarus Wealth Advisors sold 10,147 Lineage Cell Therapeutics shares in Q4 2019, an estimated $10K.
  • Clarus Wealth Advisors first reported a position in Lineage Cell Therapeutics in Q3 2019 and held it in 1 quarter.
  • Clarus Wealth Advisors's Lineage Cell Therapeutics position peaked at $10K in Q3 2019.
  • 108 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2019.

Based on Clarus Wealth Advisors's 13F filing for Q4 2019, filed 10 Jan 2020.